U.S. Markets open in 7 hrs 35 mins
  • S&P Futures

    3,263.25
    -11.75 (-0.36%)
     
  • Dow Futures

    26,957.00
    -98.00 (-0.36%)
     
  • Nasdaq Futures

    10,928.50
    -60.50 (-0.55%)
     
  • Russell 2000 Futures

    1,476.50
    -6.30 (-0.42%)
     
  • Crude Oil

    39.22
    -0.09 (-0.23%)
     
  • Gold

    1,914.60
    +4.00 (+0.21%)
     
  • Silver

    24.57
    +0.18 (+0.75%)
     
  • EUR/USD

    1.1759
    -0.0014 (-0.1176%)
     
  • 10-Yr Bond

    0.6710
    0.0000 (0.00%)
     
  • Vix

    27.78
    +1.95 (+7.55%)
     
  • GBP/USD

    1.2803
    -0.0014 (-0.1088%)
     
  • BTC-USD

    10,476.24
    +38.51 (+0.37%)
     
  • CMC Crypto 200

    222.58
    -13.00 (-5.52%)
     
  • FTSE 100

    5,804.29
    -202.76 (-3.38%)
     
  • Nikkei 225

    23,360.30
    +40.90 (+0.18%)
     

ROCE Insights For Arbutus Biopharma

Benzinga Insights

Arbutus Biopharma (NASDAQ: ABUS) reported Q2 sales of $1.51 million. Earnings fell to a loss of $13.03 million, resulting in a 0.08% decrease from last quarter. In Q1, Arbutus Biopharma brought in $1.49 million in sales but lost $13.04 million in earnings.

Why ROCE Is Significant

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Arbutus Biopharma posted an ROCE of -0.2%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

View more earnings on ABUS

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Arbutus Biopharma is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.

In Arbutus Biopharma's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.

Q2 Earnings Recap

Arbutus Biopharma reported Q2 earnings per share at $-0.25/share, which did not meet analyst predictions of $-0.24/share.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.